1. Home
  2. EIC vs NMRA Comparison

EIC vs NMRA Comparison

Compare EIC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EIC
  • NMRA
  • Stock Information
  • Founded
  • EIC N/A
  • NMRA 2019
  • Country
  • EIC United States
  • NMRA United States
  • Employees
  • EIC N/A
  • NMRA N/A
  • Industry
  • EIC Finance/Investors Services
  • NMRA
  • Sector
  • EIC Finance
  • NMRA
  • Exchange
  • EIC Nasdaq
  • NMRA Nasdaq
  • Market Cap
  • EIC 334.1M
  • NMRA 268.5M
  • IPO Year
  • EIC 2019
  • NMRA 2023
  • Fundamental
  • Price
  • EIC $12.23
  • NMRA $1.73
  • Analyst Decision
  • EIC
  • NMRA Hold
  • Analyst Count
  • EIC 0
  • NMRA 8
  • Target Price
  • EIC N/A
  • NMRA $5.83
  • AVG Volume (30 Days)
  • EIC 136.8K
  • NMRA 498.0K
  • Earning Date
  • EIC 11-13-2025
  • NMRA 11-11-2025
  • Dividend Yield
  • EIC 12.78%
  • NMRA N/A
  • EPS Growth
  • EIC N/A
  • NMRA N/A
  • EPS
  • EIC 0.70
  • NMRA N/A
  • Revenue
  • EIC $55,581,156.00
  • NMRA N/A
  • Revenue This Year
  • EIC $37.84
  • NMRA N/A
  • Revenue Next Year
  • EIC $23.33
  • NMRA N/A
  • P/E Ratio
  • EIC $17.54
  • NMRA N/A
  • Revenue Growth
  • EIC 56.39
  • NMRA N/A
  • 52 Week Low
  • EIC $12.10
  • NMRA $0.61
  • 52 Week High
  • EIC $16.71
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • EIC 28.50
  • NMRA 47.30
  • Support Level
  • EIC $12.24
  • NMRA $1.74
  • Resistance Level
  • EIC $13.40
  • NMRA $1.90
  • Average True Range (ATR)
  • EIC 0.23
  • NMRA 0.12
  • MACD
  • EIC -0.08
  • NMRA -0.02
  • Stochastic Oscillator
  • EIC 10.42
  • NMRA 10.94

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: